RSS Feeds
Search

Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..10 of 621 - per page Next page
Order by
Extracellular Matrix Gene Chips to Detect Metastatic Tumors
These gene chips detect the over-expression of the cancer-related extracellular matrix (ECM) modifier proteins Anakin and Bromodomain 4 (Brd4). More
Telomerase Suppressor Compositions and Methods for Diagnosis and Treatment of Cancer
Unique genetic changes in CCDC36 gene that are associated with early onset lung cancer More
Over-expression and Mutation of a Tyrosine Kinase Receptor FGFR4 in Tumors
Identification of mutations in fibroblast growth factor receptor 4 (FGFR4) that are associated with Rhabdomyosarcoma tumors; may be used to identify candidates for treatment with an FGFR4 inhibitor as an adjuvant to standard anticancer therapy. More
A Novel and Efficient Technology for Targeted Delivery of siRNA
Novel compositions and methods for delivering inhibitory oligonucleotides to cells in a targeted and efficient manner have been developed. More
Gene Signature for Predicting Hepatocellular Carcinoma Patient Prognosis
A method of predicting the prognosis of a patient diagnosed with HCC by detecting expression of one of more HCC-associated genes, and a method of identifying an agent for use in treating HCC More
Identification of Persons Likely to Benefit from Statin Mediated Cancer Prevention by Pharmacogenetics
A pharmacogenetic method to identify candidates who are most likely to benefit from treatment with statins to reduce cancer risk, and consequently minimizing any unnecessary cost and side effects in individuals who do not benefit. More
Predictive Medicine: Risk-adapted Therapy in Multiple Myeloma with combined abnormal Chromosomes 1 and 13 Confers Resistance to Thalidomide in Total Therapy 2 and is linked to Hyper-expression of the IL6R Gene in Malignant Plasma Cells (09-29)
Thalidomide has been successfully used to successfully treat myeloma patients however, patients with high IL6R expression levels via gene expression profiling, do not benefit from the use of this drug. Therefore, the use of anti-IL6R therapies in combina More
Risk–adapted therapy for multiple myeloma patents harboring the TP53 Deletion: The adverse consequences in Total Therapy 2 are overcome by addition of Bortezomib in Total Therapy 3 to treat the disease (09-30)
Gene array analysis and genetic testing uncovering a TP53 genetic deletion in multiple myeloma patients in combination with the use of risk-adapted therapy that incorporates thalidomide with bortezomib vastly improves patent outcomes. More
Detection of Hereditary Prostate Cancer
This technology can be used as an accurate, early prostate cancer susceptibility diagnostics method. More
Photodynamic Therapy of Cervical Cancer, Cervical Dysplasia and HPV Infection
Photodynamic Therapy of Cervical Cancer, Cervical Dysplasia and HPV Infection More
Displaying 1..10 of 621 - per page Next page
Order by

Related Reports

Market Research Reports provided by reports.iptechex.com
Diagnostics Partnering Terms and Agreements
Feb 2012 - 1350 pages - $2,695
Innovations in Oncology Diagnostics
Oct 2009 - 141 pages - $3,835
Personalized Medicine Partnering Terms and Agreements
Apr 2011 - 951 pages - $4,995
Companion Diagnostics Partnering Terms and Agreements
Apr 2011 - 250 pages - $2,695
Veterinary Diagnostics Markets
Oct 2009 - 30 pages - $995
Molecular Diagnostics: Market Landscape
Nov 2011 - 50 pages - $3,800
US Oncology, Inc.: SWOT Analysis & Company Profile
Dec 2010 - 19 pages - $99
Advancing Molecular Diagnostics to Personalize Cancer Therapy
Jun 2011 - 187 pages - $3,835
Global In-Vitro Diagnostics Market Trends
Jan 2011 - 10 pages - $500
Advances in Drug-Diagnostic Co-Development
May 2011 - 102 pages - $3,835
More Related Market Research Reports >>>

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us